News

The Manila Times16d
The United Mexican States Announces New Offering of its Global Notes and Tender Offer
NEWS MEXICO CITY, June 23, 2025 (GLOBE NEWSWIRE) -- ...
TMCnet16d
ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients
"The submission of PORTICO-2 to the FDA marks a major step forward for Oryzon and for the field of neuropsychiatry of personality disorders," said Carlos Buesa, Chief Executive Officer of Oryzon.